Phil F. Cheng

5.2k citations

96 papers · 2.9k indexed · h-index 29

Molecular Biology top 5%
Oncology top 2%
Immunology top 5%
Cancer Research top 5%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Mitchell P. Levesque Reinhard Dummer Lukas Sommer Daniel Widmer Ossia M. Eichhoff Marieke I.G. Raaijmakers Daniel Zingg Raffaella Santoro
Topics: Melanoma and MAPK Pathways (38 papers)Cancer Immunotherapy and Biomarkers (21 papers)Cutaneous Melanoma Detection and Management (18 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Journal of Clinical Investigation Nature Communications Journal of Clinical Oncology
Partner nations: Switzerland United States Germany

In The Last Decade

Phil F. Cheng

93 papers receiving 2.9k citations

Peers

Countries citing papers authored by Phil F. Cheng

Since Specialization

Citations

This map shows the geographic impact of Phil F. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil F. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil F. Cheng more than expected).

Fields of papers citing papers by Phil F. Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil F. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil F. Cheng. The network helps show where Phil F. Cheng may publish in the future.

Co-authorship network of co-authors of Phil F. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Phil F. Cheng. A scholar is included among the top collaborators of Phil F. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phil F. Cheng. Phil F. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uncovering the Distinct Role of Phleum p 4 in Grass Pollen Allergy: Sensitization Patterns in 1963 Swiss Patients 2025 ·International Journal of Molecular Sciences ·(unknown),Phil F. Cheng,Peter Schmid‐Grendelmeier,Carole Guillet	1
2	Human Dermal Microvascular Arterial and Venous Blood Endothelial Cells and Their Use in Bioengineered Dermo‐Epidermal Skin Substitutes 2025 ·Small Methods ·Dominic Rütsche,Monica Nanni,Phil F. Cheng,(unknown),Aizhan Tastanova,(unknown),Mitchell P. Levesque,Ueli Moehrlen,Agnes S. Klar,Thomas Biedermann	1
3	Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening? 2023 ·European Journal of Cancer ·(unknown),Phil F. Cheng,(unknown),Stéphanie Huber,(unknown),Julia‐Tatjana Maul,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Mitchell P. Levesque,Alexander A. Navarini,Lara Valeska Maul	32
4	Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma 2023 ·Cancer Research ·Lorenza P. Ferretti,(unknown),Deena M. Leslie Pedrioli,Phil F. Cheng,(unknown),Petra Baumgaertner,(unknown),(unknown),(unknown),Patrick Turko,Roni H. G. Wright,Katrien De Bock,Daniel E. Speiser,Roberto Ferrari,Mitchell P. Levesque,Michael O. Hottiger	11
5	Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors 2023 ·Cancer Medicine ·(unknown),Phil F. Cheng,Julia Lai‐Kwon,(unknown),Marlies Wakkee,Reinhard Dummer,Florentia Dimitriou	5
6	Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis 2023 ·Pharmaceuticals ·Lukas Kraehenbuehl,Stephanie Schneider,(unknown),Joanna Mangana,Phil F. Cheng,Reinhard Dummer,Barbara Meier	0
7	Mycobacterial infection aggravates Helicobacter pylori-induced gastric preneoplastic pathology by redirection of de novo induced Treg cells 2022 ·Cell Reports ·Mariela Artola-Borán,(unknown),(unknown),(unknown),Tim Waterboer,Anders B. Dohlman,Xiling Shen,(unknown),(unknown),Mitchell P. Levesque,Shída Yousefi,Hans‐Uwe Simon,Phil F. Cheng,Anne Müller	6
8	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis 2021 ·Cancers ·Florentia Dimitriou,(unknown),Melike Ak,(unknown),Ken Kudura,Marjam J. Barysch,Mitchell P. Levesque,Phil F. Cheng,Reinhard Dummer,Joanna Mangana	21
9	A Comparative Study of Real-Time RT-PCR–Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material 2021 ·Journal of Molecular Diagnostics ·Aizhan Tastanova,(unknown),(unknown),Phil F. Cheng,Elisa Bellini,Pål Johansen,(unknown),Stephan Nobbe,Reto Lienhard,Philipp P. Bosshard,Mitchell P. Levesque	24
10	Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma 2021 ·Non-Coding RNA ·Marina Tusup,Phil F. Cheng,Ernesto Picardi,(unknown),Reinhard Dummer,Mitchell P. Levesque,Lars E. French,Emmanuella Guenova,Thomas M. Kündig,Steve Pascolo	3
11	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases 2021 ·European Journal of Cancer ·(unknown),Florentia Dimitriou,Peter K. H. Lau,Prachi Bhave,Grant A. McArthur,Lisa Zimmer,Ken Kudura,Camille L. Gérard,Mitchell P. Levesque,Olivier Michielin,Reinhard Dummer,Phil F. Cheng,Joanna Mangana	11
12	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition 2020 ·Journal of Investigative Dermatology ·Mai Q. Nguyen,Jessica L.F. Teh,Timothy J. Purwin,Inna Chervoneva,Michael A. Davies,Katherine L. Nathanson,Phil F. Cheng,Mitchell P. Levesque,Reinhard Dummer,Andrew E. Aplin	28
13	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors 2020 ·Cancer Immunology Research ·Jessica L.F. Teh,Dan A. Erkes,Phil F. Cheng,Manoela Tiago,Nicole A. Wilski,Conroy O. Field,Inna Chervoneva,Mitch P. Levesque,Xiaowei Xu,Reinhard Dummer,Andrew E. Aplin	13
14	SMAD signaling promotes melanoma metastasis independently of phenotype switching 2019 ·Journal of Clinical Investigation ·Eylül Tuncer,(unknown),Daniel Zingg,Sandra Varum,Phil F. Cheng,Sandra N. Freiberger,Chu‐Xia Deng,Ingo Kleiter,Mitchell P. Levesque,Reinhard Dummer,Lukas Sommer	37
15	Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma 2019 ·Journal of Investigative Dermatology ·(unknown),(unknown),(unknown),Phil F. Cheng,(unknown),(unknown),(unknown),Beate M. Lichtenberger,Mitchell P. Levesque,Peter Petzelbauer	11
16	In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms 2018 ·Cancer Discovery ·Jessica L.F. Teh,Phil F. Cheng,Timothy J. Purwin,Neda Nikbakht,Prem Patel,Inna Chervoneva,Adam Ertel,Paolo Fortina,(unknown),Kim HooKim,Michael A. Davies,Lawrence N. Kwong,Mitch P. Levesque,Reinhard Dummer,Andrew E. Aplin	61
17	CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17–Mediated Psoriasiform Skin Inflammation In Vivo 2018 ·Journal of Investigative Dermatology ·Mark Mellett,Barbara Meier,Deepa Mohanan,Rebekka Schairer,Phil F. Cheng,Takashi Satoh,(unknown),Caroline Ospelt,Stephan Nobbe,Margot Thome,Emmanuel Contassot,Lars E. French	69
18	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma 2018 ·Cancer Immunology Research ·Sabrina A. Hogan,Anaïs Courtier,Phil F. Cheng,(unknown),Simone M. Goldinger,Manuarii Manuel,Solène Perez,(unknown),(unknown),Thi Dan Linh Nguyen‐Kim,Marieke I.G. Raaijmakers,Pia Kvistborg,Nicolas Pasqual,John B.A.G. Haanen,Reinhard Dummer,Mitchell P. Levesque	100
19	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma 2017 ·Cancer Research ·Karīna Siliņa,Alex Soltermann,Farkhondeh Movahedian Attar,Ruben Casanova,Zina M. Uckeley,Helen Thut,Muriel Wandres,Sergejs Isajevs,Phil F. Cheng,Alessandra Curioni‐Fontecedro,Periklis Foukas,Mitchell P. Levesque,Holger Moch,Aija Linē,Maries van den Broek	297
20	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2 2015 ·Molecular Cancer Therapeutics ·Sandra N. Freiberger,Phil F. Cheng,(unknown),(unknown),(unknown),Piotr Dziunycz,John R. Zibert,Reinhard Dummer,Kresten Skak,Mitchell P. Levesque,Günther F.L. Hofbauer	35

About Phil F. Cheng

Phil F. Cheng is a scholar working on Oncology, Dermatology and Immunology, having authored 96 papers that have together received 2.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (38 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cutaneous Melanoma Detection and Management (18 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (827 citations) and Cancer Research (433 citations). Phil F. Cheng has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Mitchell P. Levesque, Reinhard Dummer, Lukas Sommer, Daniel Widmer, Ossia M. Eichhoff, Marieke I.G. Raaijmakers, Daniel Zingg, Raffaella Santoro, Keith S. Hoek and Holger Moch. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact